115 related articles for article (PubMed ID: 36634573)
21. Clinicopathological characteristics of thyroid transcription factor 1-negative small cell lung cancers.
Iida Y; Masuda S; Nakanishi Y; Shimizu T; Nishimaki H; Takahashi M; Hikichi M; Maruoka S; Gon Y; Takahashi N; Hashimoto S
Hum Pathol; 2018 Sep; 79():127-134. PubMed ID: 29787820
[TBL] [Abstract][Full Text] [Related]
22. The expression of TTF-1 and Napsin A in early-stage lung adenocarcinoma correlates with the results of surgical treatment.
Ma Y; Fan M; Dai L; Kang X; Liu Y; Sun Y; Yan W; Liang Z; Xiong H; Chen K
Tumour Biol; 2015 Sep; 36(10):8085-92. PubMed ID: 25982999
[TBL] [Abstract][Full Text] [Related]
23. Utility of a novel triple marker (combination of thyroid transcription factor 1, Napsin A, and P40) in the subclassification of non-small cell lung carcinomas using fine-needle aspiration cases.
Sharma R; Wang Y; Chen L; Gurda GT; Geddes S; Gabrielson E; Askin F; Li QK
Hum Pathol; 2016 Aug; 54():8-16. PubMed ID: 27045515
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of thyroid transcription factor-1 in primary, resected, non-small cell lung carcinoma.
Puglisi F; Barbone F; Damante G; Bruckbauer M; Di Lauro V; Beltrami CA; Di Loreto C
Mod Pathol; 1999 Mar; 12(3):318-24. PubMed ID: 10102618
[TBL] [Abstract][Full Text] [Related]
25. Occludin is a direct target of thyroid transcription factor-1 (TTF-1/NKX2-1).
Runkle EA; Rice SJ; Qi J; Masser D; Antonetti DA; Winslow MM; Mu D
J Biol Chem; 2012 Aug; 287(34):28790-801. PubMed ID: 22761434
[TBL] [Abstract][Full Text] [Related]
26. p40 & thyroid transcription factor-1 immunohistochemistry: A useful panel to characterize non-small cell lung carcinoma-not otherwise specified (NSCLC-NOS) category.
Walia R; Jain D; Madan K; Sharma MC; Mathur SR; Mohan A; Iyer VK; Kumar L
Indian J Med Res; 2017 Jul; 146(1):42-48. PubMed ID: 29168459
[TBL] [Abstract][Full Text] [Related]
27. TTF-1 Expression Predicts the Merit of Additional Antiangiogenic Treatment in Non-squamous Non-small Cell Lung Cancer.
Takeuchi A; Oguri T; Yamashita Y; Sone K; Fukuda S; Takakuwa O; Uemura T; Maeno K; Fukumitsu K; Kanemitsu Y; Ohkubo H; Takemura M; Ito Y; Niimi A
Anticancer Res; 2018 Sep; 38(9):5489-5495. PubMed ID: 30194207
[TBL] [Abstract][Full Text] [Related]
28. Expression of thyroid transcription factor-1 in 16 human lung cancer cell lines.
Fujita J; Ohtsuki Y; Bandoh S; Ueda Y; Kubo A; Tojo Y; Yamaji Y; Ishida T
Lung Cancer; 2003 Jan; 39(1):31-6. PubMed ID: 12499091
[TBL] [Abstract][Full Text] [Related]
29. Thyroid transcription factor-1 (TTF-1) expression in human lung carcinomas: its prognostic implication and relationship with wxpressions of p53 and Ki-67 proteins.
Myong NH
J Korean Med Sci; 2003 Aug; 18(4):494-500. PubMed ID: 12923324
[TBL] [Abstract][Full Text] [Related]
30. An integrative transcriptome analysis reveals a functional role for thyroid transcription factor-1 in small cell lung cancer.
Horie M; Miyashita N; Mattsson JSM; Mikami Y; Sandelin M; Brunnström H; Micke P; Nagase T; Saito A
J Pathol; 2018 Oct; 246(2):154-165. PubMed ID: 29876935
[TBL] [Abstract][Full Text] [Related]
31. Characterizing the developmental pathways TTF-1, NKX2-8, and PAX9 in lung cancer.
Hsu DS; Acharya CR; Balakumaran BS; Riedel RF; Kim MK; Stevenson M; Tuchman S; Mukherjee S; Barry W; Dressman HK; Nevins JR; Powers S; Mu D; Potti A
Proc Natl Acad Sci U S A; 2009 Mar; 106(13):5312-7. PubMed ID: 19279207
[TBL] [Abstract][Full Text] [Related]
32. [Quantitative analysis of thyroid transcription factor-1 mRNA expressions in primary lung cancer and its metastatic foci].
Bai XY; Shen H
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jan; 28(1):20-5. PubMed ID: 18227018
[TBL] [Abstract][Full Text] [Related]
33. Clinical significance of thyroid transcription factor-1 in advanced lung adenocarcinoma under epidermal growth factor receptor tyrosine kinase inhibitor treatment.
Chung KP; Huang YT; Chang YL; Yu CJ; Yang CH; Chang YC; Shih JY; Yang PC
Chest; 2012 Feb; 141(2):420-428. PubMed ID: 21799026
[TBL] [Abstract][Full Text] [Related]
34. TTF-1 gene expression in human lung tumours.
Fabbro D; Di Loreto C; Stamerra O; Beltrami CA; Lonigro R; Damante G
Eur J Cancer; 1996 Mar; 32A(3):512-7. PubMed ID: 8814700
[TBL] [Abstract][Full Text] [Related]
35. Thyroid Transcription Factor 1 Reprograms Angiogenic Activities of Secretome.
Wood LW; Cox NI; Phelps CA; Lai SC; Poddar A; Talbot C; Mu D
Sci Rep; 2016 Feb; 6():19857. PubMed ID: 26912193
[TBL] [Abstract][Full Text] [Related]
36. Association of thyroid transcription factor-1 with the efficacy of immune-checkpoint inhibitors in patients with advanced lung adenocarcinoma.
Nakahama K; Kaneda H; Osawa M; Izumi M; Yoshimoto N; Sugimoto A; Nagamine H; Ogawa K; Matsumoto Y; Sawa K; Tani Y; Mitsuoka S; Watanabe T; Asai K; Kawaguchi T
Thorac Cancer; 2022 Aug; 13(16):2309-2317. PubMed ID: 35808895
[TBL] [Abstract][Full Text] [Related]
37. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
[TBL] [Abstract][Full Text] [Related]
38. Correlation between thyroid transcription factor-1 expression, immune-related thyroid dysfunction, and efficacy of anti-programmed cell death protein-1 treatment in non-small cell lung cancer.
Koyama J; Horiike A; Yoshizawa T; Dotsu Y; Ariyasu R; Saiki M; Sonoda T; Uchibori K; Nishikawa S; Kitazono S; Yanagitani N; Ninomiya H; Ishikawa Y; Nishio M
J Thorac Dis; 2019 May; 11(5):1919-1928. PubMed ID: 31285885
[TBL] [Abstract][Full Text] [Related]
39. Various Antibody Clones of Napsin A, Thyroid Transcription Factor 1, and p40 and Comparisons With Cytokeratin 5 and p63 in Histopathologic Diagnostics of Non-Small Cell Lung Carcinoma.
Tran L; Mattsson JS; Nodin B; Jönsson P; Planck M; Jirström K; Botling J; Micke P; Brunnström H
Appl Immunohistochem Mol Morphol; 2016 Oct; 24(9):648-659. PubMed ID: 26447895
[TBL] [Abstract][Full Text] [Related]
40. Thyroid transcription factor-1 as a prognostic indicator for stage IV lung adenocarcinoma with and without EGFR-sensitizing mutations.
Park JY; Jang SH; Kim HI; Kim JH; Park S; Hwang YI; Jung KS; Seo J; Lee CY; Ko Y; Park YB
BMC Cancer; 2019 Jun; 19(1):574. PubMed ID: 31196060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
